Bioventus Sees FY2026 Adj EPS $0.73-$0.77 vs $0.77 Est; Sees Sales $600.000M-$610.000M vs $604.182M Est

Benzinga Newsdesk Mar 5, 2026 8 months ago

NewsGuidance

2026 Financial Guidance Bioventus introduced its financial guidance for full-year 2026. The Company expects: Net sales of $600 million to $610 million. This reflects growth of approximately 6% to 7%.Adjusted

2026 Financial Guidance

Bioventus introduced its financial guidance for full-year 2026. The Company expects:

Net sales of $600 million to $610 million. This reflects growth of approximately 6% to 7%.
Adjusted EPS* of $0.73 to $0.77. This reflects an increase of approximately 7% to 13%.
Cash from Operations of $82 million to $87 million.